Celularity Inc. (NASDAQ:CELUW – Get Free Report) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totaling 106,447 shares, a growth of 89.3% from the June 30th total of 56,239 shares. Based on an average trading volume of 165,384 shares, the short-interest ratio is currently 0.6 days.
Celularity Stock Performance
Shares of CELUW stock remained flat at $0.00 during trading hours on Friday. Celularity has a 12 month low of $0.00 and a 12 month high of $0.06.
About Celularity
Celularity, Inc is a clinical-stage biotechnology company headquartered in Florham Park, New Jersey, that specializes in the development and commercialization of allogeneic “off-the-shelf” cell therapies derived from postpartum placental cells. Leveraging a proprietary platform of placental- and umbilical-derived cells, the company seeks to deliver immune-modulatory, regenerative and anti-inflammatory treatments across oncology, immunology and other therapeutic areas. By harnessing the natural properties of placental cells, Celularity aims to overcome the limitations of autologous therapies and scale production to serve a broad patient population.
The company’s pipeline includes CYNK-001, an investigational natural killer (NK) cell therapy being evaluated for hematological malignancies and solid tumors, as well as other cell-based programs targeting viral infections and tissue repair.
See Also
- Five stocks we like better than Celularity
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
